Medscape Oncology Global

Effectiveness Of Micro CME at Improving Clinical Knowledge and Competence Related to BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Presented at the 20th International **Myeloma Society (IMS) Annual Meeting and Exposition**

27-30 September, 2023

CONCLUSIONS

This study demonstrates the

success of an online CME

activity with micro video

chapters on improving the

knowledge, competence,

and confidence of hem/

oncs related to BCMA-

targeted therapies for

educational targets.

R/R MM. Additional gaps

were identified for future

Confidence improvement

has been shown to positively

correlate with an intention

to make practice changes,²

suggesting that activity

participants are likely to

apply what they learned in

Abstract ID: P-270

VICTORIA HARVEY-JONES PhD, SANNEKE KOEKKOEK: Medscape, Global Education, London, United Kingdom; SARAH E. BOMBA PharmD, BCOP: Medscape, LLC, New York, NY, USA

BACKGROUND

With B-cell maturation antigen (BCMA)-targeted therapies available for multiple myeloma (MM),

it is important that physicians are knowledgeable and competent in how to use these agents. This study aimed to determine whether online continuing medical education consisting of micro-chapters could improve the knowledge, competence, and confidence of hematologists/oncologists (hem/oncs) in managing patients with relapsed/refractory MM who are candidates for BCMA-targeted therapy.


METHODS



The educational initiative consisted of a collection of 5 online video-based micro-CME chapters, presented by three respected MM experts, allowing hem/oncs to choose the chapters for participation.¹ The activity launched 30 December 2022 with data collection through 18 April 2023.


REPEATED-PAIRS DESIGN

SAME individuals pre- and post-education




RESULTS

Improvements in percentage of correct decisions answered confidently were seen from pre- to post (36% vs 63%, *P* < .001). Overall, 68% hem/oncs improved their knowledge, competence, and confidence.



COMPETENCE RELATED TO MANAGING TREATMENT RELATED ADVERSE EVENTS OF BCMA-DIRECTED ANTIBODY DRUG CONJUGATES

There was a 23% increase in those who demonstrated mastery and 50% decrease in those who were uninformed (P = .058).



Your patient is diagnosed with R/R MM and will receive his first infusion with belantamab mafodotin later today as a part of a clinical trial. Should you recommend preservative-free lubricant eye drops in both eyes to mitigate corneal events during during treatment? (Correct Choice: Yes)

Misinformed: Confident but incorrect Uninformed: Incorrect and not confident

In a recent real-world study of idecabtagene vicleucel in patients with R/R MM,

were the levels of cytopenia comparable in patients with and without renal

insufficiency 90 days after infusion? (Correct Answer: Yes)

Doubt: Correct but not confident
Mastery: Confident and correct

Hem/Onc Specialists (n = 60) **CHI-SQUARE TEST** AGGREGATED RESULTS improved their knowledge % Correct Decisions and confidence *P* < .001 **Answered Confidently** 36%

KNOWLEDGE REGARDING BCMA-DIRECTED


BISPECIFIC ANTIBODIES

There was an 86% increase in those who demonstrated mastery

and 77% decrease in those who were uninformed (P < .01)

KNOWLEDGE REGARDING THE RATIONALE FOR **BCMA-DIRECTED THERAPIES FOR R/R MM**

There was a 225% increase in those who demonstrated mastery and 36% decrease in those who were uninformed (P < .001).



KNOWLEDGE REGARDING BCMA-DIRECTED

CAR T-CELL THERAPIES

There was a 100% increase in those who demonstrated mastery

and 86% decrease in those who were uninformed (P < .001).

Hem/Onc Specialists (n = 39) ■ Misinformed ■ Uninformed ■ Doubt ■ Mastery

Is B-cell maturation antigen (BCMA) highly expressed on early memory B cells **before differentiation?** (Correct Choice: No)


22% **52**% According to the latest data from MagnetisMM-1, were all cytokine release syndrome events experienced with elranatamab in relapsed/refractory (R/R) multiple myeloma (MM) grade 1/2? (Correct Choice: Yes)

Hem/Onc Specialists (n = 46) ■ Misinformed ■ Uninformed ■ Doubt ■ Mastery

28%

KNOWLEDGE REGARDING THE VALUE OF SOLUBLE BCMA AS A PROGNOSTIC BIOMARKER

There was a 69% increase in those who demonstrated mastery and 50% decrease in those who were uninformed (P < .01).



In general, in patients with MM, is the detection of higher levels of soluble BCMA associated with poorer clinical outcomes? (Correct Answer: Yes)

REFERENCES

1. Neri P, Raje N and Popat R. *Managing Relapsed/* Refractory Multiple Myeloma: The Ever-Expanding Role of B-Cell Maturation Antigen as a Molecular Target. Launched: 30/12/2022. Data as of 18/04/2023. Available at https://www.medscape.org/ viewarticle/986336

their practice.

2. Lucero KS, Chen P. What do reinforcement and confidence have to do with it? A systematic pathway analysis of knowledge, competence, confidence, and intention to change. *J Eur CME*. 2020;9:1834759.



This CME activity was supported by an independent educational grant from Pfizer.

DISCLOSURES

Victoria Harvey-Jones, PhD, Sarah E. Bomba PharmD, BCOP and Sanneke Koekkoek have disclosed no relevant financial relationships.

72%

36%

For more information, contact: Victoria Harvey-Jones, PhD, Clinical Strategist, Medscape Oncology Global, vharveyjones@webmd.net.

